AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Verona Pharma (VRNA)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

64.03

0.05 (0.08%)

At close: Feb 20, 2025, 3:59 PM

64.19

0.26%

After-hours: Feb 20, 2025, 04:23 PM EST

undefined% (undefined)

Bid	63
Market Cap	5.24B
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-2
PE Ratio (ttm)	-32.01
Forward PE	n/a
Analyst	Buy

Ask	64.78
Volume	709,282
Avg. Volume (20D)	1,228,303
Open	63.43
Previous Close	63.98
Day's Range	62.24 - 64.69
52-Week Range	11.39 - 65.50
Beta	undefined

About VRNA

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the ...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Apr 28, 2017

Employees 79

Stock Exchange NASDAQ

Ticker Symbol VRNA

Website https://www.veronapharma.com

Full Company Profile

Analyst Forecast

According to 7 analyst ratings, the average rating for VRNA stock is "Buy." The 12-month stock price forecast is $60, which is a decrease of -6.29% from the latest price.

Buy 100.00%

Hold 0.00%

Sell 0.00%

Stock Forecasts

Next Earnings Release

Verona Pharma is scheduled to release its earnings on Feb 27, 2025, before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

1 week ago

+5.68%

Verona Pharma shares are trading higher after Cana... Unlock content with Pro Subscription

1 month ago

+10.58%

Verona Pharma shares are trading higher following Q4 financial results.

News

1 week ago · zacks.com

What Makes Verona Pharma (VRNA) a Good Fit for 'Trend Investing'

If you are looking for stocks that are well positioned to maintain their recent uptrend, Verona Pharma (VRNA) could be a great choice. It is one of the several stocks that passed through our "Recent P...

3 weeks ago · zacks.com

Here's Why 'Trend' Investors Would Love Betting on Verona Pharma (VRNA)

Verona Pharma (VRNA) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through ...

1 month ago · zacks.com

Wall Street Analysts See a 30.65% Upside in Verona Pharma (VRNA): Can the Stock Really Move This High?

The average of price targets set by Wall Street analysts indicates a potential upside of 30.7% in Verona Pharma (VRNA). While the effectiveness of this highly sought-after metric is questionable, the ...

1 month ago · zacks.com

Verona Pharma (VRNA) Upgraded to Buy: What Does It Mean for the Stock?

Verona Pharma (VRNA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

1 month ago · zacks.com

Verona Pharma (VRNA) is on the Move, Here's Why the Trend Could be Sustainable

1 month ago · seekingalpha.com

Verona Pharma's Ohtuvayre Defies Expectations In Q4, But Stock Alpha May Now Be Limited

Verona Pharma's Ohtuvayre, a novel COPD treatment, achieved $36 million in Q4 sales, indicating strong market interest and unmet need for new therapies. Despite aggressive pricing, Ohtuvayre's broad l...